Cinpanemab

辛帕奈单抗

Report date: 2022/07/04 19:38:02

Base Information

Drug NameCinpanemab
Drug Alias NameAnti-α synuclein mAbBIIB-054
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionSynuclein alpha inhibitors
TargetsSynuclein alpha
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesItaly +[10
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNeurimmune Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiogen Inc
Active IndicationsN/A
Inactive IndicationsParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A